223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer

Jiaqiong Wang, Russ Aaron Kuker, Aldo Serafini

Research output: Contribution to journalArticlepeer-review

Abstract

A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.

Original languageEnglish (US)
Pages (from-to)e486-e488
JournalClinical nuclear medicine
Volume45
Issue number11
DOIs
StatePublished - Nov 1 2020
Externally publishedYes

Keywords

  • F-fluciclovine PET/CT
  • Ra-dichloride
  • Tc-MDP
  • bone scan
  • prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '<sup>223</sup>Ra-Dichloride Response Evaluation Using <sup>18</sup>F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient with Castration-Resistant Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this